Last updated: February 1, 2026
Executive Summary
Sodium Starch Glycolate (SSG) Type A is an excipient widely utilized in pharmaceutical formulations as a superdisintegrant. The increasing demand for oral solid dosage forms, driven by the global rise in chronic diseases, aging populations, and stringent pharmaceutical manufacturing standards, is fueling SSG Type A's market expansion. Its unique disintegration properties, cost-effectiveness, and regulatory acceptance underpin its competitiveness. This report analyzes the market size, growth drivers, competitive landscape, regulatory considerations, and financial outlook for SSG Type A, offering actionable insights for stakeholders.
Market Overview
| Parameter |
Details |
| Estimated Market Size (2022) |
USD 150 million |
| Compound Annual Growth Rate (2022-2027) |
6.5% CAGR |
| Key Consumption Regions |
North America, Europe, Asia-Pacific |
| Primary Application |
Oral solid dosage forms (tablets, capsules) |
| Major Suppliers |
FMC Corporation, Vista Pharmaceutical, ROQUETTE, MEGGLE AG |
Source: MarketsandMarkets, 2022; industry reports
What Are the Key Market Drivers for SSG Type A?
1. Rising Demand for Oral Solid Dosage Formulations
The global pharmaceutical industry’s shift toward oral solid forms—tablets and capsules—accounts for over 70% of global drug delivery routes. Superdisintegrants like SSG Type A facilitate rapid disintegration, enhancing bioavailability.
2. Aging Population and Chronic Disease Prevalence
According to World Health Organization (WHO) data, the global elderly population (65+) will reach 1 billion by 2030, augmenting demand for easy-to-administer medications requiring efficient disintegration properties.
3. Regulatory Acceptance and Patient Compliance
SSG Type A complies with pharmacopoeial standards (USP, EP, JP), simplifying regulatory approvals. Its non-toxic, inert nature boosts patient compliance especially in pediatric and geriatric formulations.
4. Cost-Effectiveness and Manufacturing Compatibility
Manufacturers favor SSG Type A for its low cost, ease of integration into existing processes, and stability profiles, supporting large-scale production.
Market Challenges and Limitations
| Challenge |
Description |
| Competition from Alternative Superdisintegrants |
Croscarmellose sodium, crospovidone, etc. |
| Regulatory Stringency Variations |
Differing international standards and approvals |
| Raw Material Price Volatility |
Maize, potato starch supply fluctuations |
| Technological Advancements |
Novel excipients emerging with superior properties |
Market Segmentation Analysis
By Application
| Segment |
Market Share (2022) |
Growth Potential |
| Tablets |
65% |
High, driven by blockbuster drugs |
| Capsules |
25% |
Moderate, niche applications |
| Others (orally disintegrating films) |
10% |
Emerging |
By Region
| Region |
Market Share (2022) |
CAGR (2022-2027) |
Drivers |
| North America |
35% |
6.0% |
USA’s dominant pharma industry |
| Europe |
25% |
6.4% |
EU regulatory harmonization |
| Asia-Pacific |
30% |
8.0% |
Cost advantages, emerging markets |
| Rest of World |
10% |
5.5% |
Growing pharmaceutical R&D |
Competitive Landscape
| Company |
Market Share (Estimated, 2022) |
Key Strengths |
| FMC Corporation |
30% |
Broad excipient portfolio, R&D capabilities |
| Vista Pharmaceutical |
20% |
Cost-effective production, regional focus |
| Roquette |
15% |
High-quality standards, global reach |
| Meggle AG |
10% |
Niche applications, innovative formulations |
| Others |
25% |
Diverse regional suppliers |
Note: The remaining market is fragmented with multiple regional players and private label suppliers.
Regulatory Environment Impacts
Global Standards and Approvals
- United States Pharmacopeia (USP): SSG recognized as a superdisintegrant under USP-NF monograph.
- European Pharmacopoeia (EP): Similar recognition, with specifications for subgroups.
- Japanese Pharmacopoeia (JP): Inclusion for direct use in formulations.
Implications
Regulatory acceptance reduces barriers to market entry, promotes wider adoption, and influences new formulation development.
Financial Trajectory and Projection
Historical Financials (Sample Data, 2018-2022)
| Year |
Revenue (USD millions) |
CAGR |
Notes |
| 2018 |
110 |
— |
Baseline year |
| 2019 |
118 |
7.3% |
Rising demand |
| 2020 |
130 |
10.2% |
COVID-induced R&D surge |
| 2021 |
143 |
10% |
Recovery and growth |
| 2022 |
150 |
4.9% |
Market stabilization |
Projected Financials (2023-2027)
| Year |
Estimated Revenue (USD millions) |
CAGR |
Assumptions |
| 2023 |
160 |
6.7% |
Market expansion continues |
| 2024 |
170 |
6.3% |
R&D pipelines and approvals |
| 2025 |
180 |
5.9% |
New markets entry |
| 2026 |
190 |
5.6% |
Regulatory harmonization |
| 2027 |
200 |
5.3% |
Market maturation |
Impacts of raw material prices, technological innovations, and regulatory shifts are anticipated to influence these figures.
Comparison with Other Disintegrants
| Parameter |
Sodium Starch Glycolate Type A |
Croscellulose Sodium |
Crospovidone |
| Disintegration Speed |
Moderate |
Fast |
Very fast |
| Cost |
Lower |
Higher |
Higher |
| Compatibility |
Excellent |
Excellent |
Good |
| Regulatory Acceptance |
High |
High |
High |
| Application Range |
Wide |
Wide |
Narrow |
FAQs
Q1: How does sodium starch glycolate Type A compare to Type B?
A: Type A and B differ structurally; Type A has a more porous matrix resulting in faster disintegration rates suitable for immediate-release formulations, while Type B provides slower disintegration, preferred in controlled-release products.
Q2: What are the raw materials primarily used in SSG Type A production?
A: Typically, maize, potato, or tapioca starch is chemically processed to produce SSG Type A, with maize starch being the most common due to stability and cost factors.
Q3: What are the key factors influencing raw material price fluctuations?
A: Weather conditions, agricultural outputs, geopolitical issues, and demand-supply dynamics in the food and pharmaceutical sectors.
Q4: What technological innovations are emerging in SSG development?
A: Nano-structured SSG variants, environmentally friendly processing methods, and enhanced disintegration efficiency via cross-linked formulations.
Q5: What is the outlook for patent protection for SSG Type A?
A: Generally, patents for manufacturing processes or specific formulations are in force for 20 years from the filing date; innovation can extend or strengthen market positioning.
Key Takeaways
- Market Growth: The SSG Type A market is projected to grow at a CAGR of approximately 6.5% through 2027, driven by the global rise in oral drug formulations.
- Industry Demand: Its cost-effectiveness, regulatory acceptance, and functional advantages underpin sustained demand, especially in emerging markets.
- Competitive Positioning: Leading players like FMC and Roquette dominate, but price-sensitive regions foster regional manufacturing.
- Regulatory Landscape: Harmonization of pharmacopoeial standards eases market entry, though raw material price volatility remains a risk.
- Financial Outlook: Revenue is expected to reach USD 200 million by 2027, contingent on technological innovation and raw material stability.
References
[1] MarketsandMarkets, "Pharmaceutical Excipient Market," 2022.
[2] WHO, “Aging and Chronic Disease Data,” 2021.
[3] USP, "Pharmacopoeia Standards for Sodium Starch Glycolate," 2022.
[4] Industry Reports, "Competitive Landscape for Pharmaceutical Disintegrants," 2022.
